Sustained improvements in workplace and household productivity and social participation with certolizumab pegol over 96 weeks in patients with psoriatic arthritis

Objectives: To examine the long-term effect of certolizumab pegol (CZP) on workplace and household productivity up to 96 weeks (wks) in patients with active psoriatic arthritis (PsA). Methods: The ongoing RAPID-PsA trial (NCT01087788) is double-blind and PBO-controlled to Wk24, dose-blind to Wk48 and open-label to Wk216. Patients had active PsA and had failed ≥ 1 DMARD. Patients originally randomized to CZP (200mg Q2W or 400mg Q4W, following 400mg loading dose [LD] at Wks 0, 2, 4) continued on their assigned dose in the OLE; PBO patients entering dose-blind phase were re-randomized to CZP LD followed by CZP 200mg Q2W or 400mg Q4W after Wk24 or, for non-responders, Wk16. The validated arthritis-specific Work Productivity Survey (WPS) administered Q4W from baseline (BL), assessed the impact of PsA on workplace and household productivity in the randomized set. WPS responses (LOCF imputation) in patients originally randomized to CZP groups are summarized descriptively over 96 wks. Results: 409 patients were randomized, of whom 273 received CZP 200mg Q2W or CZP 400mg Q4W. Of patients randomized to CZP, 91% completed Wk24, 87% Wk48 and 80% Wk96. In employed patients in both CZP groups (60.8% of all CZP patients at BL), decreases in absenteeism and presenteeism to Wk24 were continued up to Wk96 (BL: mean 2.0 and 1.6 days missed/ month in the CZP 200mg Q2W and 400mg Q4W groups, respectively; mean 5.2 and 5.1 days with reduced productivity/month vs Wk96: mean 0.3 and 0.4 days missed/ month; mean 0.7 and 1.5 days with reduced productivity/month). Improvements in household productivity and social participation reported in both CZP groups over 24 wks were also maintained to Wk96. Conclusions: The initial improvements with CZP in workplace and household productivity, and social participation were sustained up to 96 wks in PsA patients.